Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials
Summary Endpoints
     
clinical deteriorationclinical improvementdeathsviral clearance
favipiravir 1--- 3.73 [1.10; 12.65], 1 RCT, I2=0%
unassessable degree of certainty
Amantadine0----
ASC09/ritonavir0----
azithromycin0----
azvudine0----
baloxavir marboxil0----
bromhexine0----
carrimycin0----
chloroquine and derivatives0----
danoprevir / ritonavir0----
darunavir cobicistat0----
doxycycline0----
Emtricitabine/tenofovir plus colchicine plus rosuvastatin0----
Ensitrelvir (XOCOVA)0----
favipiravir plus interferon0----
fluvoxamine0----
hydroxychloroquine plus macrolides0----
Interferon plus lopinavir/ritonavir0----
ivermectin0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir0----
lopinavir/ritonavir plus chloroquine0----
Lopinavir/ritonavir plus hydroxychloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
lopinavir/ritonavir, ribavirin and interferon beta-1b0----
molnupiravir0----
niclosamide0----
nirmatrelvir / ritonavir (Paxlovid)0----
nitazoxanide0----
opaganib0----
oseltamivir0----
oseltamivir plus chloroquin0----
remdesivir0----
ribavirin0----
ritonavir0----
sofosbuvir0----
sofosbuvir and daclatasvir0----
sofosbuvir and ledipasvir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
tranilast0----
triazavirin0----
umifenovir (arbidol)0----
zinc0----

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons